Deciphera Pharmaceuticals’ Post

Gen AI + Pharmaceutical Industry = Wonder Drug? Well that’s what the latest collaboration between AstraZeneca and Absci seems to be heralding - a faster, more targeted cancer treatment. The JV includes an upfront commitment, substantial R&D funding, milestone payments, and royalties on future product sales. What other real world applications of Gen AI would 2024 bring for us? Let me know down below!

#VisionLead Oncology Drugs dominate the Pharmaceuticals market, and they're expected to keep growing, especially due to progress in immuno-oncology. However, these drugs are often expensive, mainly because there are only a few of them that are high-priced. Wealthier countries contribute most to the revenue, and for many big pharmaceutical companies, oncology is their primary market. Predictions suggest that the Oncology Drugs market will hit US$188.20 billion in revenue by 2023, and it's projected to grow annually at a rate of 13.95% (CAGR 2023-2028), reaching a market volume of US$361.60 billion by 2028.

For an Aggregate of ~2.4B, AstraZeneca to Acquire Fusion Pharmaceuticals for the Development of Radioconjugates #astrazeneca #fusionpharmaceuticals #fpi2265 #metastaticcastrationresistant #prostatecancer #mergerandacquisition #agreement #radioconjugates #development #mcrpc #cancertreatment

Kumquat Biosciences Inc. has handed over cancer-fighting drug rights to Takeda Pharmaceuticals in exchange for up to $130 million. Takeda will get an exclusive, global, and royalty-bearing license to develop and commercialize Kumquat's therapeutic, plans to undertake all the development and commercialization activities beyond Kumquat's Phase 1 trial. If all future milestones are met, Takeda could pay more than $1.2 billion, plus tiered royalties on sales. For more details on this and Kumquat’s plans to initiate a Phase 1 clinical trial of its immuno-oncology small molecule inhibitor early next year, get full subscriber access at SDBJ.com. #pharmaceuticals #oncology #kumquat #takeda #fightcancer #endcancer https://lnkd.in/gmVN9fEN

In light of Global Biosimilars Week, we are sharing key educational insights into the evolution of biosimilars. The development of biosimilars has had a significant impact on costs for clinical trials, helping to bring safe and effective drugs to market at an affordable price. Clinical Services International (CSI) specialises in sourcing both biologics and biosimilars and has supplied them to more than 700 oncology studies globally. Find out more about these revolutionising biopharmaceuticals and how CSI can provide cost savings for your trial: https://hubs.ly/Q028cX9W0 #GlobalBiosimilarsWeek #ComparatorSourcing

New Week, New Fast Fact's Friday! Here are the Fast Facts for 1/12: - After two successful Phase 3 Trials, Astellas Pharma was positioned to have the first approved therapy for claudin (CLDN) positive tumors. However, the Japanese company must now clear up manufacturing issues, following a CRL from the FDA. Read more: (https://lnkd.in/eJM-6GCf) - Only a month after closing the $43 billion acquisition of Seagen, Pfizer continues to be on the hunt for antibody-drug conjugates (ADC) according to Chief Oncology Officer Chris Boshoff Read more: (https://lnkd.in/eGvNxSu3) - BioMarin Pharmaceutical Inc. CEO Alexander Hardy announces the departure of Chief Commercial Officer Jeffrey Ajer, in a shake-up looking to boost launch success for Voxzogo & Roctavian Read more: (https://lnkd.in/es_2NAMd) - After a few months of reports coming from the FDA's Adverse Event Reporting System (FAERS), a preliminary evaluation showed no evidence linking Novo Nordisk's & Eli Lilly and Company's GLP-1 treatments to suicidal thoughts & actions Read more: (https://lnkd.in/ePtrjjQ9) #pharma #biotech #meddevice #jpm2024

🔥 Richardson Round Up 🔥 There has been some huge news in the market this week, check my previous post to see what else has happened..... some huge collaborations and investments! Let's round up the rest of the news. 💲 Pfizer have completed the acquisition of Seagen, this now means that Pfizer’s oncology portfolio includes over 25 approved medicines and biosimilars across more than 40 indications. 💲 Alkermes to Sell Mfg. Facility in Ireland to Novo Nordisk. They plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing of the transaction, which may continue through the end of 2025. 🤝 Charles River Laboratories have entered into an agreement with CELLphenomics GmbH,  The enhanced offering will provide Charles River clients with access to CELLphenomics’ 3D tumour model platform to further optimise oncological approaches for its clients. 🤝 Depixus has entered a collaboration with Daiichi Sankyo, Inc. to use their novel MAGNA technology to accelerate Daiichi's RNA-targeted drug discovery program. #cdmo #pharma #pharmaceutical #biosimilars #oncology

Cheers to PharmaEssentia for winning the Asia Pacific Enterprise Awards 2023 Taiwan under the Corporate Excellence category in the Healthcare, Pharmaceutical & Biotechnology industry. PharmaEssentia Corp. headquartered in Taipei, Taiwan, is a leading fully integrated biopharmaceutical company in Taiwan. Founded in 2000, PharmaEssentia aims to deliver new biologics for challenging diseases in hematology and oncology, currently with one approved product and a diversifying pipeline. PharmaEssentia is pursuing surging growth in four areas: further penetration of BESREMi® in key global markets; geographically expanding BESREMi® beyond the countries where it is currently approved; expanding additional indications for BESREMi® in MPNs and solid tumors; and advancing a pipeline of best-in-class/first-in-class therapies. The latter area includes new long-acting cytokines with PharmaEssentia’s innovative PEG platform, immunotherapy candidates, and innovative cell therapies. If PharmaEssentia has piqued your interest, take a closer look at its achievements here https://lnkd.in/gcfwv8yr #APEA #APEATW2023 #TAIWAN